Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108,380,780
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
30,998,695
-
Shares change
-
+432,510
-
Total reported value, excl. options
-
$618,964,700
-
Value change
-
+$11,707,281
-
Put/Call ratio
-
78.56%
-
Number of buys
-
51
-
Number of sells
-
-42
-
Price
-
$19.97
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q2 2018
111 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q2 2018.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30,998,695 shares
of 108,380,780 outstanding shares and own 28.6% of the company stock.
Largest 10 shareholders include FMR LLC (3,355,785 shares), FRANKLIN RESOURCES INC (2,970,465 shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2,745,705 shares), BlackRock Inc. (2,311,641 shares), Polar Capital LLP (1,650,715 shares), Vivo Capital, LLC (1,647,214 shares), Sofinnova Ventures Inc (1,539,480 shares), D. E. Shaw & Co., Inc. (1,268,915 shares), VANGUARD GROUP INC (1,196,843 shares), and CITADEL ADVISORS LLC (868,230 shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.